이뮨온시아, 면역함암제 임상1상 결과 공개
[Korean News] http://health.chosun.com/news/dailynews_view.jsp?mn_idx=332960
사노피 출신 대표가 이끌고, 유한이 선택한 ‘그 회사’
[Korean News] http://www.hitnews.co.kr/news/articleView.html?idxno=11928
ImmuneOncia has been selected by the Korea Drug Development Fund to develop an immune therapy targeting a cancer-aiding protein.
[English News] http://koreajoongangdaily.joins.com/news/article/article.aspx?aid=3066955 [Korean News] https://www.mk.co.kr/news/it/view/2019/08/639790/
Yuhan Corp and Sorrento Therapeutics announce completion of phase 1 clinical study of anti-PD-L1 antibody IMC-001
[English News] https://www.globenewswire.com/news-release/2019/03/11/1751072/0/en/Yuhan-Corp-and-Sorrento-Therapeutics-Announce-Completion-of-Phase-1-Clinical-Study-of-Anti-PD-L1-Antibody-IMC-001.html [Korean News] http://news.mtn.co.kr/newscenter/news_viewer.mtn?gidx=2019031117401578487
Yuhan Corp and Sorrento Therapeutics announce closing of a $40M USD Financing for joint venture ImmuneOncia to support advancement of Immuno-Oncology program
[English News] https://globenewswire.com/news-release/2019/02/12/1720647/0/en/Yuhan-Corp-and-Sorrento-Therapeutics-Announce-Closing-of-a-40m-USD-Financing-for-Joint-Venture-ImmuneOncia-to-Support-Advancement-of-Immuno-Oncology-Program.html [Korean News] http://news.mtn.co.kr/newscenter/news_viewer.mtn?gidx=2019021216104393438
Sorrento’s and Yuhan’s joint venture, ImmuneOncia, receives approval to begin clinical trial of anti-PD-L1 monoclonal antibody in South Korea
https://www.globenewswire.com/news-release/2018/02/05/1332835/0/en/Sorrento-s-and-Yuhan-s-Joint-Venture-ImmuneOncia-receives-Approval-to-begin-clinical-trial-of-Anti-PD-L1-Monoclonal-Antibody-in-South-Korea.html